The New England Comparative Effectiveness Public Advisory Council (New England CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The New England CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the New England CEPAC process, and find out how topics are selected.

New England CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the New England CEPAC must meet ICER’s criteria for Conflict of Interest.

The box below provides information on the topic of the next meeting of the New England CEPAC. For more information about past and other upcoming meetings, see the box to the right.


Next Meeting

March 24, 2017 9:30AM-4PM (ET)

The Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA 02115

Arthritis

The New England CEPAC will convene in March 2017 to discuss ICER's report on treatments for rheumatoid arthritis.

The webcast will be available at the following link beginning at 9:30AM ET: http://icer.bizvision.com/webcast/prod/83883

Register or Register for the Live Webcast

Arthritis

Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, affecting approximately 1.5 million Americans. RA is more common in women and may occur at any age, with peak incidence occurring at ages 50-60 years. RA is typically characterized by morning stiffness and symmetrical joint swelling of the feet, hands, and knees, although any joint (and in some cases, internal organs) may be involved. The course of RA may be complicated by cardiac, hematologic, and other extra-articular manifestations.

Interventions of Interest (subject to change):

TNF Inhibitors

  • Adalimumab (Humira®, Abbvie)
  • Certolizumab pegol (Cimzia®, UCB)
  • Etanercept (Enbrel®, Amgen)
  • Golimumab (Simponi®, Janssen)
  • Infliximab (Remicade®, Janssen)

CD20- directed cytolytic antibody

  • Rituximab (Rituxan®, Genentech)

Tcell inhibtor

  • Abatacept (Orencia®, BMS)

IL-6 inhibitors

  • Sarilumab (Sanofi)
  • Tocilizumab (Actemra®, Genentech)

JAK- inhibitors

  • Tofacitinib (Xeljanz®, Pfizer)
  • Baricitinib (Eli Lilly and Co.)

Date of Review: March 2017

 

View materials